COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors.
JNCI Cancer Spectr
; 5(3): Pkab049, 2021 06.
Article
in English
| MEDLINE | ID: covidwho-1292069
ABSTRACT
The study objective was to identify sociodemographic and coronavirus disease 2019 (COVID-19) factors that are associated with COVID-19 vaccine hesitancy among adolescent and young adult (AYA) cancer survivors. Eligible participants were 18 years or older and were diagnosed with cancer as an AYA (ages 15-39 years) and received services through an AYA cancer program. A total of 342 participants completed a cross-sectional survey. Our primary outcome-COVID-19 vaccine hesitancy-was surveyed as a 5-point Likert scale and operationalized as a binary outcome (agree vs hesitant). A large proportion of participants reported COVID-19 vaccine hesitancy (37.1%). In the multivariable regression, female survivors (odds ratio = 1.81, 95% confidence interval = 1.10 to 2.98) and survivors with a high school education or less (odds ratio = 3.15, 95% confidence interval = 1.41 to 7.04) reported higher odds of vaccine hesitancy compared with their male or college graduate or higher counterparts. COVID-19 vaccine hesitancy persists among AYA survivors despite their recommended priority vaccination status and higher chances of severe COVID-19 outcomes.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cancer Survivors
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Vaccination Hesitancy
/
Neoplasms
Type of study:
Observational study
/
Prognostic study
/
Qualitative research
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Young adult
Language:
English
Journal:
JNCI Cancer Spectr
Year:
2021
Document Type:
Article
Affiliation country:
Jncics
Similar
MEDLINE
...
LILACS
LIS